multiple myeloma - 2nd line (L2) | |
multiple myeloma - 2nd line (L2) | |
pembrolizumab based treatment | |
pembrolizumab plus pomalidomide and dexamethasone | KEYNOTE-183 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -